Rhythm Pharmaceuticals Announces Positive IMCIVREE® Sales and Pipeline Advancements
• Rhythm Pharmaceuticals reports preliminary unaudited net revenues of approximately $42 million for Q4 2024 and $130 million for full year 2024 from global IMCIVREE® sales.
• Topline data from the Phase 3 trial of setmelanotide in acquired hypothalamic obesity (HO) is expected in the first half of 2025.
• A new Phase 2 trial exploring setmelanotide in Prader-Willi syndrome (PWS) is planned to commence in the first quarter of 2025.
• Enrollment is completed in the Phase 3 EMANATE trial substudies for genetically-caused MC4R pathway diseases, with topline data anticipated in H1 2026.
© Copyright 2025. All Rights Reserved by MedPath